Composition and method for treatment of dry eye syndrome
AssigneeOculiant LLC
InventorsHenry M. Grage, Jr., Ajit Nemi
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods of treatment for Dry Eye Syndrome wherein they do not irritate an eye of a human patient who is in need thereof. In particular the invention provides methylglyoxal and Manuka honey in ratios and grades that relieve symptoms and causes of DES without causing irritation to the affected eye(s).
Claims20
A composition for treatment of Dry Eye Syndrome (DES), wherein the composition is aqueous and comprises:
- a) boric acid in a concentration ranging from 0.5 to 2.0 mg/mL;
- b) a boric acid salt in a concentration ranging from 0.0 to 0.5 mg/mL by dry weight as added to the composition;
- c) one or more metal chloride salts in a total concentration ranging from 3.0 to 10.0 mg/mL;
- d) a water-soluble hyaluronate polymer in a concentration ranging from 0.5 to 2.5 mg/mL;
- e) a water-soluble cellulose polymer in a concentration ranging from 2.5 to 7.5 mg/mL;
- f) a polyhydric alcohol selected from the group consisting of natural monosaccharides, sugar alcohols, amino sugars, and dihydroxypropanes, wherein the polyhydric alcohol is present in a concentration ranging from 2.0 to 20.0 mg/mL glycerin;
- g) a chlorite or hypochlorite salt, in a concentration ranging from 0.01 to 0.10 mg/mL;
- h) a pharmaceutically effective amount of added methylglyoxal (MGO) in a concentration ranging from 0.01 to 0.10 mg/mL;
- and
- i) a pharmaceutically effective amount of manuka honey in a concentration ranging from 0.5 to 1.5 mg/mL;
- wherein the methylglyoxal and manuka honey are in a ratio of respective concentrations that is in a range of 1:10 to 1:50, and
- wherein each of methylglyoxal and manuka honey is at a concentration that is not irritating when administered to an eye of a human patient who suffers from DES.
A method of therapeutic treatment for dry eye syndrome (DES) comprising administering to a patient in need thereof a pharmaceutically efficacious amount of an aqueous composition comprising:
- a) boric acid in a concentration ranging from 0.5 to 2.0 mg/mL;
- b) a boric acid salt in a concentration ranging from 0.0 to 0.5 mg/mL;
- c) one or more metal chloride salts in a total concentration ranging from 3.0 to 10.0 mg/mL;
- d) a water-soluble hyaluronate polymer in a concentration ranging from 0.5 to 2.5 mg/mL;
- e) a water-soluble cellulose polymer in a concentration ranging from 2.5 to 7.5 mg/mL;
- f) a polyhydric alcohol selected from the group consisting of natural monosaccharides, sugar alcohols, amino sugars, and dihydroxypropanes, wherein the polyhydric alcohol is present in a concentration ranging from 2.0 to 20.0 mg/mL glycerin;
- g) a chlorite or hypochlorite salt, in a concentration ranging from 0.01 to 0.10 mg/mL;
- h) a pharmaceutically effective amount of added methylglyoxal (MGO) in a concentration ranging from 0.01 to 0.10 mg/mL;
- and
- i) a pharmaceutically effective amount of manuka honey in a concentration ranging from 0.5 to 1.5 mg/mL;
- wherein the methylglyoxal and manuka honey are in a ratio of respective concentrations that is in a range from 1:10 to 1:50, and
- wherein each of methylglyoxal and manuka honey is at a concentration that is not irritating when administered to an eye of a human patient who suffers from DES.
Dependencies are inferred from the claim text.